Eligible studies reported overall survival (OS) in patients with breast cancer spinal metastases, stratified by immunohistochemistry-based subtype: hormone receptor (HR +), human epidermal growth factor receptor 2-enriched (HER2 +), and triple-negative breast cancer (TNBC). This evidence concerns the gene ERBB2 and breast carcinoma.